BXRX =MC $52 M--FDA Decision in Q1 for attractive Drug Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BXRX =MC $52 M--FDA Decision in Q1 for attractive Drug

BXRX 0.0218

+7.4%

Feb 29 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: BioHero	2/21/2020 3:32:11 PM
	of 9

Still a massive buying opportunity at current laughable valuation of only $87 million Baudax Bio's (BXRX) Non-opioid Pain Drug Makes It To The Finish Line ... rttnews.com ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing. Baudax expects ANJESO to be available in the U.S. in late April or early May 2020. Esther Hong, an analyst at Janney Montgomery, estimates peak sales of the drug in the U.S. to reach about $355 million.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext